SEC Form 4 · accession 0001225208-19-000576
BOSTON SCIENTIFIC CORP · BSX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin J. Ballinger
Officer — EVP & Pres, Interven Cardio
Period of report
Jan 3, 2019
Accepted (ET)
Jan 4, 2019 · 4:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000885725
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Jan 3, 2019 | S | 2,140 | $34.2127 | D | 82,223 | D | |
| Common StockF4,F3 | Jan 3, 2019 | S | 12,600 | $33.5507 | D | 69,623 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.
- F2Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $34.10 to $34.29, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.
- F4Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $33.05 to $34.04, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.